We have previously shown that targeting the KIT signaling pathway vertically at different nodes (i.e., at KIT using IM, in combination with downstream inhibition of AKT) demonstrated significant efficacy in an IM-sensitive GIST model. This evidence concerns the gene KIT and gastrointestinal stromal tumor.